PDE4 Inhibitor Eliminates Breast Cancer Stem Cells via Noncanonical Activation of mTOR

The effects of rolipram, a PDE4 inhibitor, were evaluated on PI3K regulators and signaling. The efficacy of rolipram was compared with paclitaxel, an anticancer drug that is ineffective in obliterating breast CSCs.